Payment overview · 2025
General Payments
$67.53
4 reported records · 3 companies
Healthcare provider profile · identity verified
William J Slusher, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · JONESBORO, LA · NPI 1649240383
Verified facts
What the public records show
CMS Open Payments records show William J Slusher, M.D. received $67.53 in general payments during 2025 across 4 reported records.
Lilly USA, LLC accounted for 53.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.06 | 53.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.77 | 24.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.70 | 21.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $67.53 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $38.77 | 2 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 88 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 482 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 448 | 99 |
| Atorvastatin Calcium | Atorvastatin Calcium | 432 | 96 |
| Losartan Potassium | Losartan Potassium | 297 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 265 | 70 |
| Lisinopril | Lisinopril | 248 | 59 |
| Eliquis | Apixaban | 232 | 28 |
| Furosemide | Furosemide | 226 | 50 |
| Gabapentin | Gabapentin | 218 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 187 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 185 | 37 |
| Metformin Hcl | Metformin Hcl | 182 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 180 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 167 | 39 |
| Potassium Chloride | Potassium Chloride | 161 | 38 |
| Nifedipine Er | Nifedipine | 145 | 39 |
| Omeprazole | Omeprazole | 134 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 42 |
| Sertraline Hcl | Sertraline Hcl | 115 | 25 |
| Metformin Hcl Er | Metformin Hcl | 107 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 18 |
| Ozempic | Semaglutide | 97 | 18 |
| Allopurinol | Allopurinol | 90 | 19 |
| Jardiance | Empagliflozin | 88 | 19 |
| Donepezil Hcl | Donepezil Hcl | 83 | 17 |
| Memantine Hcl | Memantine Hcl | 79 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 73 | 56 |
| Meloxicam | Meloxicam | 70 | 26 |
| Alendronate Sodium | Alendronate Sodium | 69 | 22 |
| Montelukast Sodium | Montelukast Sodium | 67 | 17 |
| Lorazepam | Lorazepam | 64 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 16 |
| Farxiga | Dapagliflozin Propanediol | 61 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 22 |
| Benazepril Hcl | Benazepril Hcl | 57 | suppressed |
| Valsartan | Valsartan | 56 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 15 |
| Simvastatin | Simvastatin | 53 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 52 | suppressed |
| Cefdinir | Cefdinir | 51 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | suppressed |
| Clonazepam | Clonazepam | 46 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 43 | suppressed |
| Finasteride | Finasteride | 42 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 17 |
| Spironolactone | Spironolactone | 42 | suppressed |
| Atenolol | Atenolol | 41 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | 11 |
| Azithromycin | Azithromycin | 37 | 34 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 35 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 34 | 14 |
| Celecoxib | Celecoxib | 32 | 13 |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 28 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 25 | suppressed |
| Prednisone | Prednisone | 25 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 22 | 14 |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 11 |
| Ramipril | Ramipril | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 19 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Carvedilol | Carvedilol | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Glimepiride | Glimepiride | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 12 | 11 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $67.53 · 4 records | Lilly USA, LLC | DALVANCE, JARDIANCE, MOUNJARO, UBRELVY, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error